Literature DB >> 8584483

Snake F(ab')2 antivenom from hyperimmunized horse: pharmacokinetics following intravenous and intramuscular administrations in rabbits.

S Pepin1, C Lutsch, M Grandgeorge, J M Scherrmann.   

Abstract

PURPOSE: The pharmacokinetics of a currently available horse F(ab')2 antivenoms to Vipera aspis, V. ammodytes, and V. berus (Ipser Europe) and a new more purified and pasteurized preparation (SAV) was investigated in the rabbit.
METHODS: An immunoradiometric assay using an affinity-purified goat IgG horse F(ab')2 specific and the same IgG labelled with iodine 125 as a tracer was developed. The limit of quantification in plasma was 0.032 microgram/ml. Specificity study showed that mouse F(ab')2 and Fab did not cross-react.
RESULTS: Pharmacokinetic analysis showed that the plasma F(ab')2 concentration followed a biexponential decline after intravenous bolus administration with distribution and elimination half-lives of 2.66 +/- 0.18 hrs and 49.69 +/- 4.13 hrs, respectively. The total volume of distribution (Vdss or Vd beta) was between 209 and 265 ml.kg-1 and was similar to the volume of the extracellular fluid in the rabbit (300 ml.kg-1). Total body clearance ranged from 3.33 to 3.96 ml.h-1.kg-1. After intramuscular administration which was only investigated with SAV, Tmax was 48 hrs and the absolute bioavailability was 42%.
CONCLUSIONS: No difference in pharmacokinetics was observed between the two antivenom preparations following the intravenous administration. In contrast, a reduced rate and extent of absorption was shown following intramuscular administration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8584483     DOI: 10.1023/a:1016279219619

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  12 in total

1.  Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody.

Authors:  D M Goldenberg; J A Horowitz; R M Sharkey; T C Hall; S Murthy; H Goldenberg; R E Lee; R Stein; J A Siegel; D O Izon
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

2.  Novel anti-digoxin monoclonal antibodies with different binding specificities for digoxin metabolites and other glycosides.

Authors:  D Wahyono; M Piechaczyk; C Mourton; J M Bastide; B Pau
Journal:  Hybridoma       Date:  1990-12

3.  Isolation of IgGT from hyperimmune horse anti-snake venom serum: its protective ability.

Authors:  I Fernandes; H A Takehara; I Mota
Journal:  Toxicon       Date:  1991       Impact factor: 3.033

4.  Pharmacokinetics of 125I-labelled antivenin to the venom from the scorpion Androctonus amoreuxi.

Authors:  M Ismail; A M Shibl; A M Morad; M E Abdullah
Journal:  Toxicon       Date:  1983       Impact factor: 3.033

5.  Serum levels of the immunoglobulins IgG and IgG(T) in horses.

Authors:  N Ek
Journal:  Acta Vet Scand       Date:  1974       Impact factor: 1.695

6.  Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients.

Authors:  M R Buist; P Kenemans; W den Hollander; J B Vermorken; C J Molthoff; C W Burger; T J Helmerhorst; J P Baak; J C Roos
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

7.  The plasma disposition and renal elimination of digoxin-specific Fab fragments and digoxin in the rabbit.

Authors:  M P Timsina; D S Hewick
Journal:  J Pharm Pharmacol       Date:  1992-10       Impact factor: 3.765

8.  Pharmacokinetics of radiolabeled monoclonal antibody B6.2 in patients with metastatic breast cancer.

Authors:  D F Hayes; M R Zalutsky; W Kaplan; M Noska; A Thor; D Colcher; D W Kufe
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

9.  The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.

Authors:  T Salmonson; B G Danielson; B Wikström
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

10.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

View more
  4 in total

Review 1.  Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation.

Authors:  José María Gutiérrez; Guillermo León; Bruno Lomonte
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Asp Viper (Vipera aspis) envenomation: experience of the Marseille Poison Centre from 1996 to 2008.

Authors:  Luc de Haro; Mathieu Glaizal; Lucia Tichadou; Ingrid Blanc-Brisset; Maryvonne Hayek-Lanthois
Journal:  Toxins (Basel)       Date:  2009-11-24       Impact factor: 4.546

3.  Population Pharmacokinetics of an Indian F(ab')2 Snake Antivenom in Patients with Russell's Viper (Daboia russelii) Bites.

Authors:  Geoffrey K Isbister; Kalana Maduwage; Ana Saiao; Nicholas A Buckley; Shaluka F Jayamanne; Shahmy Seyed; Fahim Mohamed; Umesh Chathuranga; Alexandre Mendes; Chandana Abeysinghe; Harindra Karunathilake; Indika Gawarammana; David G Lalloo; H Janaka de Silva
Journal:  PLoS Negl Trop Dis       Date:  2015-07-02

4.  Intravenous Vipera berus Venom-Specific Fab Fragments and Intramuscular Vipera ammodytes Venom-Specific F(ab')2 Fragments in Vipera ammodytes-Envenomed Patients.

Authors:  Tihana Kurtović; Svjetlana Karabuva; Damjan Grenc; Mojca Dobaja Borak; Igor Križaj; Boris Lukšić; Beata Halassy; Miran Brvar
Journal:  Toxins (Basel)       Date:  2021-04-14       Impact factor: 4.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.